Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by houbahopon Oct 17, 2019 12:59pm

69 Views

Post# 30240515

RE:RE:RE:Bottom

"This is not just about legacy analysts.Of course they have turned sour on TH because of poor performance , poor execution, poor and opaque communication etc etc..."

Theratechnologies has a long, long history of poor communication and lack of transparency.
It is in their DNA.
Very difficult to call a bottom on such a falling knife with a history of burning its shareholders.

Bullboard Posts

Rich TV Live's Stocks to Watch this week (Nov. 22, 2024)